康柏西普不同给药方案治疗DME的安全性和疗效评估  

Safety and efficacy of different loading doses followed by pro re nata regimens of Conbercept in the treatment of diabetic macular edema

作　　者：孟婷 孙洪岩 罗彬 王晶 汪丽玉 高亚莉 蒋莉 王君 邓铤明 曾爱能 罗小玲 杨明明 Ting Meng;Hong-Yan Sun;Bin Luo;Jing Wang;Li-Yu Wang;Ya-Li Gao;Li Jiang;Jun Wang;Ting-Ming Deng;Ai-Neng Zeng;Xiao-Ling Luo;Ming-Ming Yang(Shenzhen People's Hospital,the Second Clinical Medical College of Jinan University,the First Affiliated Hospital of Southern University of Science and Technology,Shenzhen 518003,Guangdong Province,China;Guizhou Medical University,Guiyang 550001,Guizhou Province,China;Guangdong Medical University,Zhanjiang 524023,Guangdong Province,China)

机构地区：[1]中国广东省深圳市人民医院暨南大学第二临床医学院南方科技大学第一附属医院,518003 [2]贵州医科大学,贵州省贵阳市550001 [3]广东医科大学,广东省湛江市524023

出　　处：《国际眼科杂志》2023年第1期138-141,共4页International Eye Science

基　　金：国家自然科学基金项目(No.82000768);深圳市基础研究专项(深圳市自然科学基金)面上项目(No.JCYJ20210324113808023)。

摘　　要：目的:评估康柏西普采用连续3次每月注射后改用按需治疗方案(3+PRN)和连续5次每月注射后改用按需治疗方案(5+PRN)治疗糖尿病性黄斑水肿(DME)的安全性和疗效。方法:回顾性病例对照研究。选取2019-12/2020-06期间于我院就诊的DME患者51例92眼纳入研究,据治疗方案分为3+PRN组(26例48眼)和5+PRN组(25例44眼)。治疗后至少随访12mo,观察两组患者最佳矫正视力(BCVA)和中心凹视网膜厚度(CMT)的变化情况,玻璃体腔注药次数及眼部不良事件发生率。结果:随访12mo,3+PRN组、5+PRN组患者平均注药次数无差异(7.24±0.91次vs 7.56±1.04次,P=0.117)。治疗后3、6、9、12mo,两组患者BCVA和CMT均较治疗前改善(均P<0.05),且治疗后6、9、12mo,5+PRN组患者BCVA和CMT均优于3+PRN组(均P<0.05)。随访期间,两组患者均未发生严重不良事件,两组患者眼部不良事件总发生率均为27%,所有不良事件给予对症处理后均好转。结论:康柏西普3+PRN和5+PRN治疗方案均能安全有效地治疗DME,总注射次数相当,但5+PRN治疗方案较3+PRN治疗方案视力改善更佳,CMT下降更明显。·AIM:To evaluate the efficacy and safety of different Conbercept treatment on diabetic macular edema(DME)with 3+PRN and 5+PRN.·METHODS:Retrospective case-control study.A total of 51 patients(92 eyes)with DME who were treated in our hospital during December 2019 and June 2020 were included,and they were divided into 3+PRN group with 26 cases(48 eyes)and 5+PRN group with 25 cases(44 eyes).All patients received monthly follow-up for 12 mo and the changes of best-corrected visual acuity(BCVA)and central macular thickness(CMT),the number of intravitreal injections and the occurrence of complications were compared and observed in the two groups.·RESULTS:After follow-up for 12 mo,there was no difference in the average injection times between the 3+PRN group and the 5+PRN group(7.24±0.91 times vs.7.56±1.04 times,P=0.117).The BCVA and CMT of the two groups improved at 3,6,9,and 12 mo after treatment compared with those before treatment(all P<0.05),and the BCVA and CMT of the 5+PRN group were better than those of the 3+PRN group at 6,9,and 12 mo after treatment(all P<0.05).During the follow-up period,no serious adverse events occurred in the two groups of patients,and the total incidence of ocular adverse events in the two groups was 27%.All adverse events were improved after symptomatic treatment.·CONCLUSION:Both the 3+PRN and 5+PRN treatment strategy of Conbercept can treat DME safely and effectively,the total times of injection were comparable.However,the BCVA and CMT improved more in the 5+PRN group than that in 3+PRN group.

关 键 词：康柏西普 糖尿病性黄斑水肿(DME) 按需治疗 最佳矫正视力 中心凹视网膜厚度 注射次数 

分 类 号：R774.5[医药卫生—眼科] R587.2[医药卫生—临床医学]